Skip to main content
Top
Published in: Clinical Rheumatology 5/2009

01-05-2009 | Original Article

Faraway from the Silk Route: demographic and clinical features of Behçet’s disease in 106 Brazilian patients

Authors: Fabricio Souza Neves, Cezar Augusto Muniz Caldas, Laís Verderame Lage, Cláudia Goldenstein-Schainberg, Célio Roberto Gonçalves

Published in: Clinical Rheumatology | Issue 5/2009

Login to get access

Abstract

To describe clinical and epidemiological data of Behçet’s disease (BD) in Brazil, we retrospectively reviewed records of all patients seen between 2006 and 2007 at the BD outpatient clinic of University of Sao Paulo. One hundred and six patients fulfilled the International Study Group for Behçet’s Disease diagnostic criteria and they were included in this study. There was a female/male ratio of 2.2:1 and mean age at diagnosis was 31.9 ± 9.2 years. In order of frequency, oral (100%) and genital ulcerations (92.5%), pseudofolliculitis (59.4%), erythema nodosum (49.1%), ocular lesions (47.2%), and musculoskeletal complaints (35.8%) were the most common manifestations. Blindness and major vessel involvement (18.2% vs. 5.5%, p = 0.038 and 27.3% vs. 9.6%, p = 0.019) were more frequent among male than female patients. We concluded that in Brazil, a South American country faraway from the Silk Route, BD follows the same pattern exhibited on its usual endemic area.
Literature
1.
2.
go back to reference Yurdakul S, Günaydin I, Tüzün Y et al (1988) The prevalence of Behçet’s Syndrome in a rural area in northern Turkey. J Rheumatol 15:820–822PubMed Yurdakul S, Günaydin I, Tüzün Y et al (1988) The prevalence of Behçet’s Syndrome in a rural area in northern Turkey. J Rheumatol 15:820–822PubMed
3.
go back to reference Azizlerli G, Köse AA, Sarica R et al (2003) Prevalence of Behçet’s disease in Istambul, Turkey. Int J Dermatol 42:803–806PubMedCrossRef Azizlerli G, Köse AA, Sarica R et al (2003) Prevalence of Behçet’s disease in Istambul, Turkey. Int J Dermatol 42:803–806PubMedCrossRef
4.
go back to reference Zouboulis CC (1999) Epidemiology of Adamantiades-Behçet’s disease. Ann Med Interne 150:488–498 Zouboulis CC (1999) Epidemiology of Adamantiades-Behçet’s disease. Ann Med Interne 150:488–498
5.
go back to reference Zoubolis CC, Kötter I, Djawari D et al (1997) Epidemiological features of Adamantiades-Behçet’s disease in Germany and Europe. Yonsei Med J 38:411–422 Zoubolis CC, Kötter I, Djawari D et al (1997) Epidemiological features of Adamantiades-Behçet’s disease in Germany and Europe. Yonsei Med J 38:411–422
6.
go back to reference Ehrlich GE (1997) Vasculitis in Behçet’s disease. Int Rev Immunol 14:81–88PubMed Ehrlich GE (1997) Vasculitis in Behçet’s disease. Int Rev Immunol 14:81–88PubMed
7.
go back to reference International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
8.
go back to reference Neves FS, Moraes JC, Kowalski SC, Goldenstein-Shainberg C, Lage LV, Gonçalves CR (2007) Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to the Brazilian Portuguese language. Clin Rheumatol 26:1263–1267PubMedCrossRef Neves FS, Moraes JC, Kowalski SC, Goldenstein-Shainberg C, Lage LV, Gonçalves CR (2007) Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to the Brazilian Portuguese language. Clin Rheumatol 26:1263–1267PubMedCrossRef
9.
go back to reference Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728–733CrossRef Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728–733CrossRef
10.
go back to reference Mangelsdorf HC, White WL, Jorizzo JL (1996) Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol 34:745–750PubMedCrossRef Mangelsdorf HC, White WL, Jorizzo JL (1996) Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol 34:745–750PubMedCrossRef
11.
go back to reference Houman MH, Neffati H, Braman A et al (2007) Behçet’s disease in Tunísia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol 4(Suppl 45):S58–S64 Houman MH, Neffati H, Braman A et al (2007) Behçet’s disease in Tunísia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol 4(Suppl 45):S58–S64
12.
go back to reference Bang D, Lee JH, Lee Es et al (2001) Epidemiologic and clinical survey of Behçet’s disease in Korea: the first multicenter study. J Korean Med Sci 16:615–618PubMed Bang D, Lee JH, Lee Es et al (2001) Epidemiologic and clinical survey of Behçet’s disease in Korea: the first multicenter study. J Korean Med Sci 16:615–618PubMed
13.
go back to reference Davatchi F, Sharam F, Kumar A et al (2004) Comparative analysis of Behçet’s disease in the APLAR region. APLAR Journal of Rheumatology 7:38–43CrossRef Davatchi F, Sharam F, Kumar A et al (2004) Comparative analysis of Behçet’s disease in the APLAR region. APLAR Journal of Rheumatology 7:38–43CrossRef
14.
go back to reference Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42:346–351PubMedCrossRef Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42:346–351PubMedCrossRef
15.
go back to reference Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin-Altunbas H, Urgancioglu M (2004) Uveitis in Behçet’s disease: an analysis of 880 patients. Am J Ophtalmol 138:373–380CrossRef Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin-Altunbas H, Urgancioglu M (2004) Uveitis in Behçet’s disease: an analysis of 880 patients. Am J Ophtalmol 138:373–380CrossRef
16.
go back to reference Chang HK, Cheon KS (2002) The clinical significance of a pathergy reaction in patients with Behçet’s disease. J Korean Med Sci 17:371–374PubMed Chang HK, Cheon KS (2002) The clinical significance of a pathergy reaction in patients with Behçet’s disease. J Korean Med Sci 17:371–374PubMed
17.
go back to reference Krause I, Moland Y, Mitrani M, Weinberger A (2000) Pathergy reaction in Behçet’s disease: lack of correlation with mucocutaneous manifestation and systemic disease expression. Clin Exp Rhematol 18:71–74 Krause I, Moland Y, Mitrani M, Weinberger A (2000) Pathergy reaction in Behçet’s disease: lack of correlation with mucocutaneous manifestation and systemic disease expression. Clin Exp Rhematol 18:71–74
Metadata
Title
Faraway from the Silk Route: demographic and clinical features of Behçet’s disease in 106 Brazilian patients
Authors
Fabricio Souza Neves
Cezar Augusto Muniz Caldas
Laís Verderame Lage
Cláudia Goldenstein-Schainberg
Célio Roberto Gonçalves
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1081-z

Other articles of this Issue 5/2009

Clinical Rheumatology 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine